NCT06556407 (RDN-HD) is a NA clinical trial of renal denervation in Treatment Resistant Hypertension, sponsored by University of Erlangen-Nürnberg Medical School.

Who is sponsoring NCT06556407?

NCT06556407 is sponsored by University of Erlangen-Nürnberg Medical School.

What drugs are being tested in NCT06556407?

Interventions in NCT06556407: renal denervation.

What condition does NCT06556407 study?

NCT06556407 studies Treatment Resistant Hypertension, Chronic Hemodialysis.

Is NCT06556407 still recruiting?

NCT06556407 is currently recruiting now. Last updated 26 September 2025.

Last reviewed 2025-09-26 · How we verify

NCT06556407: RDN-HD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Renal Denervation on Bood Pressure in Patients on Hemodialysis

Recruiting now NA Last updated 26 September 2025

What this trial tests

NA trial testing renal denervation in Treatment Resistant Hypertension in 12 participants. Currently enrolling.

Timeline

4 March 2024

Primary endpoint
1 December 2026

1 December 2026

Quick facts

Lead sponsor	University of Erlangen-Nürnberg Medical School
Phase	NA
Status	Recruiting now
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	12
Start date	4 March 2024
Primary completion	1 December 2026
Estimated completion	1 December 2026
Sites	1 location across Germany

Drugs / interventions tested

renal denervation

Conditions studied

Treatment Resistant Hypertension — all drugs for Treatment Resistant Hypertension →
Chronic Hemodialysis — all drugs for Chronic Hemodialysis →

Sponsor

University of Erlangen-Nürnberg Medical School

Who can join

Adults 18 to 99, any sex, with Treatment Resistant Hypertension or Chronic Hemodialysis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The RDN-HD Study is a prospective, single-center feasibility study. All patients included will undergo endovascular ultrasound-based RDN (no sham group, no blinding). The purpose of the RDN-HD Study is to demonstrate that ultrasound-based RDN is safe in patients with TRH and ESRD hemodialysis and reduces 24-h ambulatory BP.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and Efficacy of Renal Denervation for the Treatment of Resistant Hypertension in Patients with Chronic Kidney Disease: A Narrative Review of the Literature.
Iliakis P, Dimitriadis K, Tatakis F, Vakka A, et al · · 2025 · cited 1× · PMID 40868205 · DOI 10.3390/biomedicines13081951

Verify or expand the search:

Other trials of renal denervation

Trials testing the same drug.

NCT07320768 — Renal Denervation Combined With Pulsed Field Ablation to Prevent Blanking-Period Recurrence in Persistent Atrial Fibrill · NA · not yet recruiting
NCT04182620 — Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation · NA · completed
NCT01583881 — Denervation of the renAl sympathetIc nerveS in hearT Failure With nOrmal Lv Ejection Fraction · Phase 2, PHASE3 · terminated

Other recruiting trials for Treatment Resistant Hypertension

Currently open trials in the same condition.

NCT06940011 — Endocalyx in Treatment Resistent Hypertension · Phase 2 · recruiting

Other University of Erlangen-Nürnberg Medical School trials

Trials by the same sponsor.

NCT06969820 — Establishment and Evaluation of Standardized Clinical, Biological and Imaging Parameters to Assess the Response of LDRT · not yet recruiting
NCT07406191 — WB-EMS Effects on Cardiometabolic Risk Factors · NA · recruiting
NCT07352540 — Single vs Triple Hyaluronic Acid in Knee Osteoarthritis · Phase 2, PHASE3 · not yet recruiting
NCT07313878 — Evaluation of Acute and Chronic Nephrotoxicity in Acute Lymphatic Leukemia Patients Using Ultrasound Localization Micros · NA · recruiting
NCT07121985 — Multispectral Optoacoustic Imaging for the Detection of Inflammation and Damage of Peripheral Nerves in Guillain-Barré S · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06556407 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Erlangen-Nürnberg Medical School
Last refreshed: 26 September 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06556407.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing